Introduction {#s1}
============

Rationale
---------

Occupation-related cancers are an important public health issue with serious socioeconomic effects. It is essential to recognize and identify occupational carcinogens for risk prevention, surveillance, and compensation of exposed workers. According to data from the International Agency for Research on Cancer (IARC), hexavalent chromium \[Cr(VI)\] has been classified as a Group I occupational carcinogen. In addition, there is sufficient evidence that Cr(VI) is related to cancers of the lung, nasal cavity, and paranasal sinuses ([@B1]). The European Commission conducted a socioeconomic, health, and environmental impact assessment and found that strong factors related to attributable cancer deaths include hardwood dust, Cr(VI), and respirable crystalline silica ([@B2]). Cr(VI) exposure exists in many industries, including chromate production, stainless steel production, welding, chrome pigment production, chrome plating, tanning, cement production, and aircraft manufacturing. Workers are often exposed to Cr(VI) by inhalation and dermal contact ([@B3]). A meta-analysis performed by Welling et al. suggested that Cr(VI) is a stomach carcinogen in humans ([@B4]). Hara et al. found that Cr(VI) exposure may increase the risk of brain cancer and malignant lymphoma ([@B5]). Iaia et al. confirmed that exposure to Cr(VI) increased lung, bladder, and pancreatic cancer mortality among tanners and found that Cr(VI) increased mortality due to myeloid leukemia and tumors of the endocrine glands ([@B6]).

Great progress has been made in identifying the correlation between exposure to Cr(VI) and some respiratory cancers. Nevertheless, there is an ongoing need for research on the relationship between Cr(VI) and other cancers, which has not been evaluated owing to inadequate epidemiological evidence and a paucity of quantitative exposure data.

Research Question
-----------------

Does Cr(VI) pose a risk of increased cancer incidence and mortality in populations with high exposure to Cr(VI)?

Materials and Methods {#s2}
=====================

This study was conducted following the 2015 Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) and the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines ([@B7], [@B8]), which was shown in [Supplemental Table 4](#SM4){ref-type="supplementary-material"}.

Search Strategy
---------------

Databases (PubMed, EMBASE, Web of Science, the Cochrane Library, Google Scholar, CNKI, WANFANG, and VIP) were searched by two authors independently to obtain all related epidemiological data up to May 28, 2018. The data covered the period 1985--2016. The search strategies used combinations of the following keywords and phrases: hexavalent chromium, chromium(VI), Cr(VI), chromate, chrome, chromate production, stainless steel, welding, chrome pigment production, chrome plating, ferrochrome production, leather, tanning, tanners, cement, concrete, metal plating, cancer, neoplasia, neoplasm, tumors, malignant neoplasms, malignancy, cohort study, cancer mortality, cancer incidence, cancer morbidity, standardized mortality ratio (SMR), standardized incidence ratio (SIR), with "AND" and "OR" used to narrow the range of articles identified. In addition, we searched all studies in the reference lists of published reviews and all relevant meta-analyses.

Selection Criteria
------------------

All contents of the candidate articles and data were read, and the data were extracted by two authors (DYJ and WM) independently. Publications included in this meta-analysis met the following criteria: (1) the exposed population and study region was stated; (2) the exposure factor was clear and exposure was to Cr(VI); (3) the cancer mortality or incidence data were included; (4) the study was a cohort study; (5) the exposure time and dose were declared; (6) a follow-up period was included; (7) the SMR or SIR with confidence intervals (CIs) were listed; (8) for studies with different latency periods, the SMR/SIR for the longest period was selected; (9) for studies with different exposure levels, the result of the highest level was selected.

The exclusion criteria were as follows: (1) unavailable data (no CIs of SMR or SIR, or only data of relative risk, odds ratio, proportional mortality ratio, or hazard ratio); (2) duplicated data; for overlapping populations, only the largest number of cases or most recent data were selected; (3) meta-analysis study, case report, review, or letter; (4) occupational exposure to materials other than Cr(VI), such as asbestos or nickel;(5) unpublished data, including government reports; (6) professions such as shoemaking (non-leather) or general building work; (7) exposure to Cr(VI) in drinking water.

Quality Assessment
------------------

Each study was assigned a quality score based on the Newcastle-Ottawa assessment scale (NOS) ([@B9]), by two authors independently, to ensure the research quality. Any disagreements were discussed among the group members until consensus was reached. NOS scores range from 0 to 9; the NOS score of the studies included in this meta-analysis ranged from 6 to 8.

Data Extraction
---------------

The following data were extracted by two authors independently: first author\' name, publication year, country in which the study was conducted, sex of the study population, exposure time, follow-up period, cancer incidence rate, cancer types, occupations, number of cancer-specific deaths, study design, outcome indicator, and standardized mortality ratios (SMRs) or standardized incidence ratios (SIRs) with their 95% CIs.

Statistical Analysis
--------------------

The meta-SMRs and SIRs with their 95% CIs were calculated using either a fixed or random-effects model to evaluate the mortality and incidence of human cancers. The Cochran Q test and *I*^2^ statistic were used to assess heterogeneity. Heterogeneity was considered significant with *P* \< 0.10 or *I*^2^ \> 50%. The random-effects model was used for values of *I*^2^ \> 50%, and the fixed-effects model was applied otherwise. Subgroup analyses were carried out according to geographical region, sex, cancer type, and profession, to screen susceptible populations and high-risk diseases. Begg\'s funnel plot and Egger\'s test were used to estimate publication bias ([@B10], [@B11]). Asymmetry in the funnel plot exists with a value of *P* \< 0.05 in the Egger\'s test, indicating significant publication bias. A sensitivity analysis including more than 10 studies was conducted, to assess the individual effect of each study on the results. All statistical tests were two-sided, with *P* \< 0.05 indicating statistical significance. Stata version.14.0 (Stata Corp LL, College Station, TX, USA) was used to analyze the data.

Results {#s3}
=======

Study Selection and Characteristics
-----------------------------------

Of nearly 700 entries initially identified in the database search, only 512 articles were included after duplicates were removed and full texts were read carefully. The specific screening procedures are listed in the flow chart ([Figure 1](#F1){ref-type="fig"}). We ultimately included 37 cohorts with SMRs reported and 16 with SIRs reported (retrospective or historical prospective) from 47 separate studies. The total number of cases was 1,141,094, ranging from 198 to 892,591 cases per study. Included studies covered 14 countries including the United States, Unite Kingdom, Finland, France, Korea, Japan, Germany, Italy, Lithuania, Sweden, Switzerland, Iceland, Denmark, and Norway. The study populations included both male and female workers who were occupationally exposed to Cr(VI), such as chromate production workers, cement industry workers, stainless steel welders, chrome platers, aircraft manufacturing workers, tanners, painters, and masons. In most studies, the exposure time to Cr(VI) was more than 1 year. Key characteristics of the included studies are summarized in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}. All the results of subgroup analysis were shown in [Supplementary Tables 1](#SM1){ref-type="supplementary-material"}, [2](#SM2){ref-type="supplementary-material"}. Studies excluded from this meta-analysis and the reasons for exclusion are shown in [Supplementary Table 3](#SM3){ref-type="supplementary-material"}.

![Flow chart of the study procedure.](fonc-09-00024-g0001){#F1}

###### 

Characteristics and results of SMR studies included in the meta-analysis.

  **Study**                    **Country**   **District**    **Sex**   **No of cases**   **Cancer deaths (Observed)**   **Exposure time(year)**   **Follow-up time**                                        **Cancer type**   **Occupation**                   **Effect measure**   **SMR**   **95% CI**   **NOS score**   
  ---------------------------- ------------- --------------- --------- ----------------- ------------------------------ ------------------------- --------------------------------------------------------- ----------------- -------------------------------- -------------------- --------- ------------ --------------- ---
  Proctor et al. ([@B12])      USA           North America   male      714               167                            \>1                       1940--2011, 34.4 (0.1--69.9) years, 24,535 person-years   Lung cancer       Chromate production workers      SMR                  1.86      1.45         2.28            8
  Proctor et al. ([@B12])      USA           North America   male      198               37                             1                         1940--2011, 6,549 person-years                            mixed             Chromate production workers      SMR                  1.28      0.87         1.69            7
  Gibb et al. ([@B13])         USA           North America   male      2,354             460                            6.4-57.2                  1950--2011, 38.9 (+/−14.2) years, 91,186 person-years     mixed             Chromate production workers      SMR                  1.16      1.06         1.27            8
  Huvinen et al. ([@B14])      Finland       Europe          mix       8,088             133                            24.7                      1971--2012, 199,760 person-years                          mixed             Chromate production workers      SMR                  0.88      0.73         1.03            8
  Dab et al. ([@B15])          France        Europe          mix       9,118             207                            \>1                       1990--2005, 13.4 years, 122,124 person-years              mixed             Cement production workers        SMR                  0.8       0.69         0.92            8
  Koh et al. ([@B16])          Korea         Asia            male      5,146             103                            35.3(9.6)                 1992--2007, 74,123 person-years                           mixed             Cement production workers        SMR                  0.83      0.68         1.01            7
  Lipworth et al. ([@B17])     USA           North America   mix       7,458             980                            \>1                       1960--2008, 226,885 person-years, 31.8 years              mixed             Aircraft Manufacturing Workers   SMR                  0.99      0.92         1.05            8
  Hara et al. ([@B5])          Japan         Asia            mix       1,193             97                             \>0.5                     1976--2003, 27 years, 26,000 person-years                 mixed             Chromium platers                 SMR                  1.05      0.86         1.27            8
  Birk et al. ([@B18])         Germany       Europe          mix       901               47                             \>1                       1958--1998, 14,700 person-years                           mixed             Chromate production workers      SMR                  0.98      0.72         1.3             7
  Iaia et al. ([@B6])          Italy         Europe          mix       972               21                             \>1                       1970--1998, 14,402 person-years                           mixed             Tanners                          SMR                  0.66      0.44         0.95            7
  Park et al. ([@B19])         Korea         Asia            male      44,974            801                            \>1                       1992--2001, 414,259 person-years,10 years                 mixed             Welders                          SMR                  0.79      0.7          0.9             8
  Park et al. ([@B20])         USA           North America   male      2,357             122                            3.1                       1950--1992                                                Lung cancer       Chromium workers                 SMR                  1.78      1.5          2.11            6
  Smailyte et al. ([@B21])     Lithuania     Europe          male      2,498             121                            \>1                       1978--2000, 43,490 person-years                           mixed             Cement production workers        SMR                  1.3       1            1.5             7
  Stern et al. ([@B22])        USA           North America   mix       9,352             548                            \>1                       1940--1993, 265,499 person-years                          mixed             Tanners                          SMR                  0.9       0.83         0.98            7
  Luippold et al. ([@B23])     USA           North America   mix       482               90                             \>1                       1940--1997, 14,048 person-years                           mixed             Chromate production workers      SMR                  1.55      1.25         1.91            7
  Steenland et al. ([@B24])    USA           North America   male      4,459             258                            \>2 (8.5)                 1988--1998                                                mixed             Welders                          SMR                  1.25      1.09         1.41            6
  Moulin et al. ([@B25])       France        Europe          mix       4,897             216                            \>1 (16.7)                1968--1992, 18.1 years, 87,247 person-years               mixed             Welders                          SMR                  0.97      0.85         1.11            8
  Sorahan et al. ([@B26])      UK            Europe          mix       1,087             131                            \>0.25                    1972--1997                                                mixed             Chromium platers                 SMR                  1.35      1.12         1.62            6
  Boice et al. ([@B27])        USA           North America   mix       3,634             251                            \>1                       1960--1996, 88,224 person-years (mean 24.2 years)         mixed             Aircraft Manufacturing Workers   SMR                  0.93      0.82         1.06            8
  Sorahan et al. ([@B28])      UK            Europe          male      1,762             65                             \>0.5                     1946--1995, 48135.1 person-years                          Lung cancer       Chromium platers                 SMR                  1.25      0.93         1.66            7
  Montanaro et al. ([@B29])    Italy         Europe          mix       1,244             123                            \>0.5                     1955--1994,36 414 person-years                            mixed             Tanners                          SMR                  1.12      0.94         1.34            7
  Jakobsson et al. ([@B30])    Sweden        Europe          male      727               61                             \>1                       1952--1993,15 years                                       mixed             Welders                          SMR                  0.8       0.6          1.1             7
  Fu et al. ([@B31])           UK            Europe          mix       4,215             646                            \>1                       1939--1991, 10,3726 person-years                          mixed             Tanners                          SMR                  0.75      0.69         0.81            7
  Fu et al. ([@B31])           Italy         Europe          mix       2,008             127                            \>1                       1950--1990, 54,395 person-years                           mixed             Tanners                          SMR                  1.16      0.96         1.38            7
  Mikoczy, et al. ([@B32])     Sweden        Europe          mix       2,060             119                            \>1                       1952--1989                                                mixed             Tanners                          SMR                  1.09      0.91         1.31            6
  Sorahan, et al. ([@B33])     UK            Europe          male      10,438            1.129                          \>1 (9.3)                 1946--1990, 29.2 years                                    mixed             Welders                          SMR                  1.19      1.12         1.26            7
  Korallus, et al. 1([@B34])   Germany       Europe          male      1,417             62                             \>1                       1982--1988, 12114.5 person-years                          mixed             Chromate production workers      SMR                  1.18      0.91         1.51            7
  Korallus et al 2([@B34])     Germany       Europe          male      1,417             81                             \>1                       1982--1988, 13868.2 person-years                          mixed             Chromate production workers      SMR                  1.58      1.27         1.94            7
  Moulin et al. ([@B35])       France        Europe          male      2,721             60                             \>1 (19.5)                1975--1988, 34,131 person-years                           mixed             Welders                          SMR                  0.93      0.71         1.2             7
  Jakobsson et al. ([@B36])    Sweden        Europe          male      2,391             97                             \>1                       1952--1986, 52,177 person-years                           mixed             Cement production workers        SMR                  0.83      0.68         1.02            7
  Becker et al. ([@B37])       Germany       Europe          mix       1,213             48                             \>0.5                     1983--1988, 31,122 person-years                           mixed             Welders                          SMR                  1.09      0.82         1.44            7
  Steenland et al. ([@B38])    USA           North America   male      4,459             105                            \>2                       1974--1987,8.5years                                       mixed             Welders                          SMR                  1.02      0.83         1.24            7
  Simonato et al. ([@B39])     Europe        Europe          male      11,092            303                            \>1                       1964--1984, 164,077 person-years                          mixed             Welders                          SMR                  1.13      1            1.26            7
  Moulin et al. ([@B40])       France        Europe          male      2,269             27                             \>1                       1952--1982                                                mixed             Welders                          SMR                  1.01      0.67         1.48            6
  Horiguchi et al. ([@B41])    Japan         Asia            male      265               7                              \>1                       1965--1979, 3912.1 person-years                           mixed             Chromium platers                 SMR                  1.13      0.45         2.32            7
  Costantini et al. ([@B42])   Italy         Europe          male      2,926             85                             \>0.5(12.3)               1950--1983                                                mixed             Tanners                          SMR                  0.97      0.77         1.19            6
  Guberan et al. ([@B43])      Switzerland   Europe          male      1,916             96                             \>1                       1971--1984                                                mixed             Chromium platers                 SMR                  1.27      1.07         1.51            6
  Svensson et al. ([@B44])     Sweden        Europe          male      1,164             51                             \>0.25                    1951--1983,24,624 person-years                            mixed             Welders                          SMR                  0.98      0.74         1.3             7
  Hayes et al. ([@B45])        UK            Europe          male      1,879             101                            \>1                       1940--1982, 50,724 person-years                           mixed             Chromium workers                 SMR                  0.93      0.76         1.13            7
  Rafnsson et.al. 1([@B46])    Iceland       Europe          male      449               26                             20-30                     1927--1982                                                mixed             Masons                           SMR                  1.45      0.95         2.13            6
  Rafnsson et al. 2([@B46])    Iceland       Europe          male      389               21                             20                        1951--1982                                                mixed             Masons                           SMR                  1.64      1.02         2.51            6
  Rafnsson et al. 3([@B46])    Iceland       Europe          male      251               17                             30                        1951--1982                                                mixed             Masons                           SMR                  2.23      1.3          3.57            6
  Pippard et al. ([@B47])      UK            Europe          male      260               30                             \>1                       1939--1982                                                mixed             Tanners                          SMR                  1         0.68         1.43            6

###### 

Characteristics and results of SIR studies included in the meta-analysis.

  **Study**                         **Country**   **District**    **Sex**   **No of cases**   **Cancer incidence (Observed)**   **Exposure time (year)**   **Follow-up time**                            **Cancer type**   **Occupation**            **Effect measure**   **SIR**   **95% CI**   **NOS score**   
  --------------------------------- ------------- --------------- --------- ----------------- --------------------------------- -------------------------- --------------------------------------------- ----------------- ------------------------- -------------------- --------- ------------ --------------- ---
  Huvinen et al. ([@B14])           Finland       Europe          Mix       8,146             408                               5                          1967--2011, 196,484 person-years              mixed             Welders                   SIR                  1.01      0.93         1.13            7
  Koh et al. ([@B16])               Korea         Asia            Male      5,596             174                               33.1(9)                    1992--2007, 47,233 person-years               mixed             Cement Industry Workers   SIR                  1.01      0.87         1.18            6
  Sorensen et al. ([@B48])          Denmark       Europe          Mix       4,539             421                               \>1                        1968--2003, 35 years, 125,762 person-years    mixed             Welders                   SIR                  1.02      0.93         1.13            8
  Mikoczy et al. ([@B49])           Sweden        Europe          Mix       2,027             351                               \>1                        1958--1999, 56,022 person-years               mixed             Tanners                   SIR                  1.16      1.04         1.29            7
  Smailyte et al. 1([@B21])         USA           North America   Mix       1,727             141                               \>1                        1978--2000, 43,490 person-years               mixed             Cement Industry Workers   SIR                  1.20      1.00         1.40            7
  Smailyte et al. 2([@B21])         USA           North America   Mix       771               41                                \>1                        1978--2000, 43,490 person-years               mixed             Cement Industry Workers   SIR                  0.80      0.60         1.10            7
  Knutsson et al. ([@B50])          Sweden        Europe          Female    33,503            3572                              \>1                        1971--1992,19.4 years, 582,225 person-years   mixed             Cement Industry Workers   SIR                  1.07      1.03         1.10            8
  Vasama-Neuvonen et al. ([@B51])   Finland       Europe          Male      892,591           5072                              \>1                        1971--1995, 15,481,680 person-years           Overian cancer    Chromium workers          SIR                  0.70      0.40         1.20            7
  Danielsen et al. ([@B52])         Europe        Europe          Male      426               32                                \>10                       1976--1992, 6,632 person-years                mixed             Welders                   SIR                  0.77      0.53         1.09            7
  Rafnsson et al. ([@B53])          Iceland       Europe          Male      1,172             148                               \>1                        1955--1993                                    mixed             Cement Industry Workers   SIR                  1.13      0.96         1.33            6
  Jakobsson et al. ([@B30])         Sweden        Europe          Male      719               112                               \>1                        1958--1992                                    mixed             Welders                   SIR                  0.90      0.70         1.20            6
  Danielsen et al. ([@B54])         Norway        Europe          Mix       606               41                                \>1                        1953--1992                                    mixed             Welders                   SIR                  1.00      0.71         1.35            6
  Hansen et al. ([@B55])            Denmark       Europe          Male      10,059            190                               \>1                        1964--1986                                    mixed             Welders                   SIR                  0.94      0.81         1.08            6
  Jakobsson et al. ([@B36])         Sweden        Europe          Male      2,358             162                               \>1                        1958--1986, 46,133 person-years               mixed             Cement Industry Workers   SIR                  1.01      0.86         1.18            7
  Simonato et al. ([@B39])          Europe        Europe          Male      7510              363                               \>5                        1964--1984, 98,376 person-years               mixed             Welders                   SIR                  1.20      1.08         1.33            7
  Melkild et al. ([@B56])           Norway        Europe          Male      783               252                               \>0.25                     1946--1977                                    mixed             Welders                   SIR                  1.03      0.90         1.16            6
  Svensson et al. ([@B44])          Sweden        Europe          Male      1,164             84                                \>0.25                     1958--1983, 20,936 person-years               mixed             Welders                   SIR                  1.03      0.82         1.27            7

*Mix, Male and Female; SIR, standardized incidence ratio; CI, confidence interval; LL, lower limit; UL, upper limit; NOS, The Newcastle-Ottawa quality assessment scale; mixed: Various cancer types; Europe (in country): Denmark, England, Finland, France, Germany, Italy, Norway, Scotland, Sweden*.

Cancer Mortality
----------------

There were a total of 43 SMR studies comprising 167,397 cases and 8,277 cancer deaths. The aggregate data covered all 14 countries listed above and 8 types of occupation. All studies had follow-up periods of more than 5 years. The specific follow-up information was as follows: 5- to 10-year, 11- to 20-year, 21- to 30-year, 30- to 40-year, 40- to 50-year, and more than 50-year follow-up studies accounted for 11.60%, 16.30, 14.00, 23.30, 18.60, and 16.30% of studies, respectively.

We calculated the overall cancer-specific SMR for all studies and found that significant heterogeneity existed among studies (*I*^2^ = 85.1%, *P* = 0.0001, [Figure 2](#F2){ref-type="fig"}). Therefore, the random-effects model was used and the meta-SMR was found to be 1.07 (95% CI: 1.01--1.15). In subgroup analysis by sex, we found that the SMR was higher for male workers than female ones (SMR = 1.14; 95% CI: 1.06--1.23). When subgroup analysis was conducted by geographical location, we found that Cr(VI) exposure was related to a higher risk of death owing to cancer in North America than in other regions (SMR = 1.19; 95% CI: 1.04--1.35). Among the various occupations, the meta-SMR was higher for chromate production workers (SMR = 1.24; 95% CI: 1.07--1.43) and chromium platers (SMR = 1.22; 95% CI: 1.10--1.34) than for other workers. However, the results differed for workers in Europe and Asia, cement production workers, aircraft manufacturing workers, tanners, welders, and chromium workers.

![Forest plot of studies included in this meta-analysis of hexavalent chromium with standardized mortality ratios (SMRs) of cancer.](fonc-09-00024-g0002){#F2}

Respiratory System Cancers
--------------------------

In total, 44 cohort studies were included, with 94,089 cases; a total of 2,938 patients died of respiratory system cancers. We found that Cr(VI) exposure was correlated with a high-risk of respiratory system cancer mortality (SMR = 1.33; 95% CI: 1.19--1.48). In subgroup analysis, the meta-SMR was higher in male workers than in female workers, and higher in North America and Europe than in Asia. The meta-SMR was elevated for chromate production workers, chromium platers, and welders, but not for cement production workers, aircraft manufacturing workers or tanners.

For lung cancer, the random-effects model was used for the 44 included studies (2,805 deaths), and the meta-SMR was 1.31 (95% CI: 1.17--1.47). In subgroup analysis, the meta-SMR was significantly higher among male workers, in North America, and in Europe than in female workers and in Asia. The meta-SMRs were higher in chromate production workers, chromium platers, and welders than in cement production workers, aircraft manufacturing workers, and tanners.

For larynx cancer, the fixed-effects model was applied for 18 SMR studies (100 deaths) and the meta-SMR was 1.22 (95% CI: 0.98--1.51). The results were robust when we stratified by geographical location; however, in subgroup analysis by occupation, the meta-SMR was higher in chromate production workers than in other workers. In addition, we found that the summary SMR was increased in male workers.

Digestive System Cancers
------------------------

The fixed-effects model was used (*I*^2^ = 14.8%, *P* = 0.115) for 99 studies (154,688 cases, 1,833 deaths). There were no significant association between Cr(VI) and death risk of digestive system cancers, and the meta-SMR was 0.97(95% CI: 0.92--1.01). In subgroup analysis, the results were robust for esophageal cancer, stomach cancer, pancreatic cancer, hepatobiliary system cancer, intestinal cancer, colon cancer, and rectal cancer, except for rectal cancer in Europe ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}).

Urinary System Cancers
----------------------

The fixed-effects model was used (*I*^2^ = 35%, *P* = 0.022) for 36 studies (92,532 cases, 170 deaths), and the meta-SMR was 1.20 (95% CI: 1.07--1.35). The meta-SMR was higher in male workers and higher in European workers than in North American workers. The meta-SMR was elevated for welders, but not for chromate production workers, cement production workers, aircraft manufacturing workers or tanners.

For bladder cancer, the fixed-effects model (*I*^2^ = 35.9%, *P* = 0.076) was used for 16 studies (71,950 cases, 157 deaths), and the meta-SMR was 1.24 (95% CI: 1.05--1.47). The meta-SMR was higher in male workers, and higher in European workers than in North American workers, and higher in welders than in tanners.

For kidney cancer, the fixed-effects model (*I*^2^ = 6.10%, *P* = 0.386) was used for 12 studies (62,568 cases, 87 deaths) and the meta-SMR was 1.15 (95% CI: 0.91--1.45). The results were robust when we stratified these studies by geographical location or profession ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). The meta-SMR was more significant in male workers than in female ones.

Lymphatic and Hematopoietic Cancers
-----------------------------------

The fixed-effects model (*I*^2^ = 10.20%, *P* = 0.276) was used for 47 studies (149,026 cases and 274 deaths), and the meta-SMR was 1.03 (95% CI: 0.93--1.13). The results were robust when we stratified studies by occupation or sex ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). In subgroup analysis, exposed workers in Asia had highest cancer mortality. For multiple myeloma (7 studies, 34,112 cases, 46 deaths), the meta-SMR was 1.10 (95% CI: 0.80--1.50). For leukemia (16 studies, 108,957 cases, 186 deaths), the meta-SMR was 1.00 (95% CI: 0.86--1.16). The results were robust in subgroup analysis ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). With respect to lymphoma (19 studies, 65,956 cases, 129 deaths), meta-SMR was 1.15 (95% CI: 0.96--1.39). In addition, the meta-SMR was 1.40 (95% CI: 0.87--2.25) for Hodgkin lymphoma and was 1.07 (95% CI: 0.84--1.37) for non-Hodgkin lymphoma.

Genitourinary System Cancers
----------------------------

We analyzed a total of 27 studies (65,784 cases, 315 deaths) of genitourinary system cancers, and the meta-SMR was 1.04 (95% CI: 0.93--1.17). The meta-SMR for 14 studies (61,178 cases, 254 deaths) of prostate cancer was 0.99 (95% CI: 0.87--1.12). These results were robust in subgroup analysis ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). For breast cancer (4 studies, 20,424 cases, 31 deaths), the meta-SMR was 1.12 (95% CI: 0.76--1.65). The fixed-effects model was used (*I*^2^ = 16.90%, *P* = 0.307) for testicular cancer (4 studies, 23,446 cases, 13 deaths), and the meta-SMR was 2.55 (95% CI: 1.38--4.71).

Other Types of Cancers
----------------------

For cancers of the buccal cavity and pharynx (17 studies, 58,204 cases, and 126 deaths), the meta-SMR was 0.91 (95% CI: 0.75--1.10). The results were robust in subgroup analysis ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). The combined SMR for skin cancer (6 studies, 30,243 cases, 29 deaths) was 0.99 (95% CI: 0.66--1.48). For melanoma, the meta-SMR was 0.90 (95% CI: 0.52--1.54). For connective and soft tissue cancer (3 studies including 20,444 cases and 11 deaths), the combined SMR was 1.22 (95% CI: 0.62--2.41). The meta-SMR for cancers of other sites (23 studies, 53,010 cases, 427 death) was 1.22 (95% CI: 0.98--1.51).

For cancers of the central nervous system, 9 studies (33,718 cases and 50 deaths) were analyzed and the meta-SMR was 1.22 (95% CI: 0.67--2.23). In subgroup analysis, the meta-SMR was highest among Asian workers. For brain cancer, the meta-SMR was 1.67 (95% CI: 0.62--4.46).

For bone cancer (5 studies, 24,568 cases, 12 deaths), the fixed-effects model was used (*I*^2^ = 0%, *P* = 0.422) and the meta-SMR was 2.06 (95% CI: 1.12--3.81). For thyroid cancer (3 studies, 19,109 cases, 8 deaths), the fixed-effects model was used (*I*^2^ = 31.20%, *P* = 0.234) and the combined SMR was 2.41 (95% CI: 1.19--4.87).

Cancer Incidence
----------------

In all, 973,697 workers were involved in 17 SIR studies, and 11,564 of these had cancer. In these studies, the aggregate data covered seven countries and four kinds of occupations. All studies had follow-up periods of more than 15 years; and the detailed data are: follow-up of 15--25 years (9 studies, 52.90%), 26--35 years (4 studies, 23.50%), and 36--45 years (4 studies, 23.50%).

The fixed-effects model was used (*I*^2^ = 39.4%, *P* = 0.049, [Figure 3](#F3){ref-type="fig"}) and the combined SIR was 1.06 (95% CI: 1.04--1.09). In subgroup analysis, the summary SIR was elevated for cement industry workers, and tanners, but not for welders or chromium workers. In addition, workers exposed to Cr(VI) had high cancer incidence in Europe. For workers in North America and Asia, the summary SIRs were above 1.00, but the 95% CIs included 1.00.

![Forest plot of studies included in this meta-analysis of hexavalent chromium with standardized incidence ratios (SIRs) of cancer.](fonc-09-00024-g0003){#F3}

Respiratory System Cancers
--------------------------

The fixed-effects model (*I*^2^ = 5.8%, *P* = 0.375) was used for 30 studies (22,623 cases, 1,001 cancer patients), and the meta-SIR was 1.27 (95% CI: 1.19--1.36). The meta-SIR was higher in male workers and European workers. The meta-SIR was also elevated for welders and cement production workers.

For larynx cancer (10 studies, 61,940 cases, 73 incidents), the meta-SIR was 1.14 (95% CI: 0.89--1.45). A total of 10 studies (69,883 cases, 894 incidents) of lung cancer were analyzed, and the meta-SIR was 1.28 (95% CI: 1.20--1.37) using the fixed-effects model (*I*^2^ = 35.2%, *P* = 0.093). The results were robust in subgroup analysis ([Supplementary Table 2](#SM2){ref-type="supplementary-material"}). For nasal cancer (3 studies, 10,956 cases, 6 incidents), the meta-SIR was 2.14 (95% CI: 0.79--5.80). The fixed-effects model was used (*I*^2^ = 0%, *P* = 0.764) for 3 studies (34,892 cases, 21 incidents) of pleural mesothelioma, and the meta-SIR was 1.73 (95% CI: 1.08--2.77).

Digestive System Cancers
------------------------

The fixed-effects model was used (*I*^2^ = 19.3%, *P* = 0.12) for 51 studies (65,737 cases, 1,407 incidents) of digestive system cancer, and the meta-SIR was 1.05 (95% CI: 1.00--1.11). In subgroup analysis, there were no association between Cr(VI) and esophageal cancer (55,927 cases, 58 incidents), pancreatic cancer (8 studies, 55,248 cases, 160 incidents), colon cancer (19,899 cases, 114 incidents), rectum cancer (66,508 cases, 291 incidents), and hepatobiliary system cancer (55,391 cases, 115 incidents). All these results were robust in subgroup analysis ([Supplementary Table 2](#SM2){ref-type="supplementary-material"}).

The fixed-effects model was used (*I*^2^ = 43.30%, *P* = 0.042) for 14 studies (66,508 cases, 420 incidents) of stomach cancer, and the meta-SIR was 1.20 (95% CI: 1.08--1.32). In subgroup analysis, meta-SIR was elevated in male workers, European workers, and cement production workers, but not in welders. For the 14 studies (66,508 cases, 668 incidents) of bowel cancer (intestine, colon, and rectum), the meta-SIR was 1.03 (95% CI: 0.96--1.12), with the SIR being especially high in welders.

Urinary System Cancers
----------------------

The fixed-effects model was used (*I*^2^ = 0%, *P* = 0.6) for 23 studies (62,986 cases, 562 incidents) of urinary system cancer, and the meta-SIR was 1.03 (95% CI: 0.95--1.13). In 9 studies of bladder cancer (60,489 cases, 360 incidents), the meta-SIR was 1.09 (95% CI: 0.98--1.22). In the 10 studies (54,757 cases, 175 incidents) of kidney cancer analyzed, the meta-SIR was 0.93 (95% CI: 0.79--1.08). These results were robust in subgroup analysis ([Supplementary Table 2](#SM2){ref-type="supplementary-material"}).

Genitourinary System Cancers
----------------------------

For the 13 studies (61,564 cases, 1,083 incidents) of male genital cancer and 13 studies (61,564 cases, 1,047 incidents) of prostate cancer, the combined SIR was 1.14 (95% CI: 1.07--1.21) and 1.15 (95% CI: 1.08--1.22), respectively, with the SIR being especially high among European workers. These results were robust when we stratified these studies by occupation ([Supplementary Table 2](#SM2){ref-type="supplementary-material"}).

For 8 studies (903,535 cases, 5,181 incidents) of female genital cancer, the meta-SIR was 1.02 (95% CI: 0.85--1.23). The results were robust in subgroup analysis ([Supplementary Table 2](#SM2){ref-type="supplementary-material"}). For breast cancer, the meta-SIR was 1.08 (95% CI: 0.84--1.38).

Lymphatic and Hematopoietic Cancer
----------------------------------

The fixed-effects model was used (*I*^2^ = 0%, *P* = 0.998) for 24 studies (633,367 cases, 432 incidents) of lymphatic and hematopoietic cancers, and the meta-SIR was 1.10 (95% CI: 1.00--1.22). The results were robust in subgroup analysis ([Supplementary Table 2](#SM2){ref-type="supplementary-material"}). For multiple myeloma (5 studies, 50,444 cases, 72 incidents), the meta-SIR was 1.13 (95% CI: 0.89--1.44). In the 7 studies of leukemia (53,390 cases, 148 incidents) analyzed, the meta-SIR was 1.11 (95% CI: 0.93--1.31). For lymphoma, the combined SIR of 5 studies (88,894 cases, 173 incidents) was 1.12 (95% CI: 0.96--1.30). In addition, the meta-SIR was 0.99 (95% CI: 0.65--1.52) for Hodgkin lymphoma, and 1.14 (95% CI: 0.97--1.34) for non-Hodgkin lymphoma.

Oral Cancers
------------

The fixed-effects model was used (*I*^2^ = 4.3%, *P* = 0.404) for 16 studies (59,537 cases, 163 incidents) of oral cancer (buccal cavity and pharynx), and the meta-SIR was 1.30 (95% CI: 1.11--1.54), with the SIR being especially high in male workers, Europeans and welders ([Supplementary Table 2](#SM2){ref-type="supplementary-material"}).

Cancer of Other Sites
---------------------

The meta-SIR for 4 studies (48,417 cases, 29 incidents) of thyroid cancer was 0.81 (95% CI: 0.54--1.21). Three studies of brain cancer (42,821 cases, 134 incidents) were analyzed, and the meta-SIR was 1.04 (95% CI: 0.87--1.24). The combined SIR for 13 studies (55,880 cases, 432 incidents) of skin cancer was 1.02 (95% CI: 0.95--1.10). For melanoma, 3 studies (43,802 cases, 117 incidents) were analyzed, and the meta-SIR was 0.92 (95% CI: 0.77--1.11). The meta-SIR for soft tissue cancer (3 studies, 43,676 cases, 35 incidents) was 1.20 (95% CI: 0.84--1.71). The meta-SIR of other cancers (5 studies, 43,511 cases, 180 incidents) was 1.09 (95% CI: 0.94--1.26).

Exposure Level of Cr(VI) With Incidence and Mortality Risk of Cancers
---------------------------------------------------------------------

As shown in [Table 3](#T3){ref-type="table"}, in the subgroup analysis of cumulative hexavalent exposure (mg Cr(VI)/m^3^-years), the higher the concentration of Cr(VI) in the air, the higher the risk of cancer death for workers. When the concentration is more than 1 mg Cr(VI)/m^3^, there is a significant increase of risk of cancer death. As for time since first exposure to Cr(VI), an elevated death risk of cancer was observed, especially for lung cancer.

###### 

The results of the association between different exposure level of Cr(VI) and incidence and mortality of human cancers.

  **Exposure level assessment**                                       **Number of study**   **Cancer type**     **Effect model**   **Heterogeneity**   **Outcome**   **Effect value**   **LL**   **UL**   
  ------------------------------------------------------------------- --------------------- ------------------- ------------------ ------------------- ------------- ------------------ -------- -------- ------
  **CUMULATIVE HEXAVALENT EXPOSURE (MG CR(VI)/m**^**3**^**-YEARS)**                                                                                                                                       
  \<0.5                                                               3                     All                 Fixed              0.00                0.41          SMR                1.35     0.81     2.25
  0.5--1                                                              2                     All                 Fixed              0.00                0.33          SMR                1.50     0.91     2.48
  \>1                                                                 2                     All                 Fixed              0.00                0.51          SMR                4.17     2.95     5.90
  Total                                                               7                     All                 Random             71.60               0.01          SMR                2.48     1.93     3.18
  **TIME SINCE FIRST EXPOSURE (YEARS)**                                                                                                                                                                   
  \<20                                                                17                    All                 Random             50.10               0.01          SMR                1.42     1.18     1.71
  ≥20                                                                 19                    All                 Fixed              10.30               0.33          SMR                1.55     1.27     1.89
  Total                                                               36                    All                 Fixed              36.20               0.02          SMR                1.53     1.38     1.71
  \<20                                                                14                    Lung cancer         Fixed              0.00                0.55          SMR                1.52     1.24     1.85
  ≥20                                                                 15                    Lung cancer         Fixed              49.80               0.02          SMR                1.57     1.36     1.81
  Total                                                               29                    Lung cancer         Fixed              29.50               0.07          SMR                1.55     1.38     1.74
  **DURATION OF EMPLOYMENT (YEARS)**                                                                                                                                                                      
  1--10                                                               20                    All                 Fixed              47.70               0.02          SMR                1.11     1.05     1.18
  11--20                                                              5                     All                 Fixed              20.10               0.29          SMR                0.98     0.92     1.05
  ≥21                                                                 12                    All                 Random             90.30               0.01          SMR                0.92     0.87     0.96
  Total                                                               37                    All                 Random             80.3                0.01          SMR                0.99     0.96     1.02
  1--10                                                               18                    Lung cancer         Fixed              0.01                0.48          SMR                1.32     1.21     1.43
  11--20                                                              4                     Lung cancer         Fixed              0.01                0.58          SMR                1.09     0.97     1.23
  ≥21                                                                 10                    Lung cancer         Random             91.80               0.01          SMR                1.43     1.01     2.02
  Total                                                               32                    Lung cancer         Random             80.50               0.01          SMR                1.40     1.21     1.63
  1--10                                                               2                     Colorectal cancer   Fixed              0.01                0.91          SMR                1.08     0.87     1.34
  11--20                                                              2                     Colorectal cancer   Fixed              49.70               0.16          SMR                1.00     0.79     1.27
  ≥21                                                                 3                     Colorectal cancer   Random             56.10               0.10          SMR                1.03     0.89     1.19
  Total                                                               7                     Colorectal cancer   Fixed              11.70               0.34          SMR                1.04     0.93     1.16
  1--14                                                               6                     All                 Fixed              0.00                0.88          SIR                1.13     0.90     1.40
  ≥15                                                                 4                     All                 Fixed              0.00                0.30          SIR                1.34     1.13     1.60
  Total                                                               10                    All                 Fixed              0.00                0.64          SIR                1.25     1.09     1.44

AN interesting finding is that a slight increase of death risk of cancer was observed in workers less 10 years, when the subgroup analysis of duration of employment about Cr(VI) was conducted. Further analysis revealed that long duration of exposure to Cr(VI) was associated with elevated death risk for lung cancer, but not for colorectal cancer. In SIR studies, the duration of employment was related to increased cancer risk, especially when workers were employed more than 15 years.

Publication Bias
----------------

Begg\'s funnel plot and Egger\'s test were used to investigate publication bias. We found no evidence of asymmetry in the funnel plot of all studies combined ([Figure 4](#F4){ref-type="fig"}), or in the funnel plots for each subgroup analysis ([Supplementary Table 2](#SM2){ref-type="supplementary-material"}). The results of the Egger\'s (SMR: *P* = 0.36; SIR: *P* = 0.09) and Begg\'s tests (SMR: *P* = 0.78; SIR: *P* = 0.14) also showed no significant evidence of publication bias.

![Begger\'s funnel plot of studies included in this meta-analysis of hexavalent chromium with cancer mortality and morbidity. **(A)** Begger\'s funnel plot of hexavalent chromium and SMR; **(B)** Begger\'s funnel plot of hexavalent chromium and SIR.](fonc-09-00024-g0004){#F4}

Sensitivity Analysis
--------------------

Each study was individually eliminated to assess the effect of individual studies on the results. The sensitive analysis ([Figure 5](#F5){ref-type="fig"}) showed that the results were significantly influenced by two studies ([@B31], [@B33]). Therefore, the meta-SMR was calculated after excluding these two studies, resulting in a slightly higher meta-SMR (1.08 vs. 1.07). As shown in [Figure 6](#F6){ref-type="fig"}, there was no significant change in the merged SIRs, which indicated the stability of results.

![Results of sensitivity analysis for SMRs.](fonc-09-00024-g0005){#F5}

![Results of sensitivity analysis for SIRs.](fonc-09-00024-g0006){#F6}

Discussion {#s4}
==========

Summary of the Main Findings
----------------------------

In this meta-analysis, we identified 47 studies specifically investigating cancer mortality or incidence in relation to Cr(VI) exposure among workers. Overall, our meta-analysis provided evidence that Cr(VI) might cause cancers of the respiratory system, buccal cavity and pharynx, prostate, and stomach in humans. This findings differ from the conclusions of Donato et al. ([@B57]), who suggested that Cr(VI) was related to increased risk of cancer incidence of the lung, larynx, bladder, kidney, testis, thyroid, and bone. In addition, the incidence and death risk of cancer was associated significantly with concentration of Cr(VI) in the air and the exposure time.

The overall cancer mortality risk of 1.07 indicated that workers exposed to Cr(VI) had a higher risk of cancer death compared with their age-matched and sex-matched counterparts in the general population. For lung cancer, a significant relationship existed between exposure to Cr(VI) and cancer death. This result was consistent with a previous meta-analysis conducted by Cole et al. that included 49 SMR epidemiological studies and showed that Cr(VI) was a weak cause of lung cancer ([@B58]). Moreover, we found that Cr(VI) was related to a higher risk of larynx cancer mortality, especially among chromate production workers. The meta-analysis did not find evidence for increased risk of death due to digestive system cancers, which was accordant with a formal meta-analysis performed by Proctor et al. Those authors analyzed 32 SMR studies and found that workers exposed to Cr(VI) were not at a higher risk of death owing to gastrointestinal tract cancer ([@B59]). However, our analysis of 14 studies showed that the meta-SMR was high for rectal cancer in Europe; these results must be confirmed in further studies.

A major finding here was that for workers exposed to Cr(VI), the mortality risk of urinary system cancer and bladder cancer was high. Among male workers, the meta-SMR of kidney cancer was high. In addition, the present meta-analysis provided additional evidence for elevated risk of death owing to testicular, bone, and thyroid cancers among workers exposed to Cr(VI), however, additional epidemiological evidence is needed to verify the accuracy of these results. However, the associations between exposure to Cr(VI) and the high mortality of some cancers were not significant, like those of breast, lymphatic, and hematopoietic, buccal cavity and pharynx, central nervous system, skin, and connective and soft tissue cancers.

The summary SIR of 1.06 (95% CI: 1.04--1.09) provided evidence for increased risk of cancer among workers exposed to Cr(VI), as compared with the general population. The narrow CI, which excludes 1.0, and the low *I*^2^ value indicate that this result was not due to chance, to a large extent. We also performed subgroup analysis by sex, occupation, cancer type, and geographical location to explore more specific relationships. The results were robust for cement industry workers and tanners, especially in Europe. For studies in North America and Asia, the summary SIR was above 1.00, but the 95% CI included 1.00. For respiratory system cancers, the meta-SIR was elevated, especially in male workers, European workers and welders. The associations were strong and robust for lung cancer and pleural mesothelioma, but not for larynx cancer and nasal cancers. Kim et al. suggested that there was no strong evidence of an association of Cr(VI) with nasal and paranasal cancers ([@B60]). However, in 2015, Binazzi et al. conducted a meta-analysis of risk ratios in 28 studies (11 cohort, 17 case-control) and suggested that sinonasal cancer was associated with exposure to nickel and chromium compounds ([@B61]). Therefore, more studies of these cancer types are urgently needed.

A novel finding was that workers exposed to Cr(VI) were at risk of oral cancer. Yuan et al. suggested that nickel and chromium play a role in oral cancer ([@B62]). The present meta-analysis showed that the risk for genital cancers, such as prostate cancer, was elevated in male workers. With respect to the digestive system, the summary SIR was elevated among exposed workers only for stomach cancer and, not for esophageal, pancreatic, intestinal, colon, rectal, or hepatobiliary system cancers. This finding is in agreement with the results of the meta-analysis performed by Welling et al. ([@B4]), as previously described. These results were also consistent with the conclusion of a previous meta-analysis of pancreatic cancer by Ojajarvi et al. Those authors analyzed 92 studies on occupational exposures and found that the meta-risk ratio for chromium was 1.40 (95% CI: 0.90--2.30) ([@B63]); the established causal relationship between exposure to Cr(VI) and lymphatic and hematopoietic cancer was found to be weak.

The cohort studies included here were carried out during different time periods, which may account in part for the heterogeneity, even though all follow up periods of the included studies were more than 5 years. However, the distribution of the six follow-up periods in the included SMR studies was well-proportioned, so the heterogeneity may be alleviated to a certain extent. The proportion of occupation types included in the analysis varied: chromate production workers, welders, and tanners comprised nearly 20% each, whereas, other occupations comprised 5--10%. The varying exposure times may be another source of heterogeneity, even though the exposure times of the included cohorts were mostly over 1 year. To some extent, the study populations included in the meta-analysis, which were from different geographical regions, may cause bias and heterogeneity. The SMR is a reflection of relative ratio and depends on the adjustment of confounders in the study and reference populations. Most studies in this meta-analysis included adjustment for confounding factors, such as age and sex.

There is some evidence that clarifies the carcinogenesis of Cr(VI) exposure. In 2014, Ovesen declared that long-term exposure to low-concentrations of Cr(VI) could induce DNA damage ([@B64]). Wang et al. found that chronic Cr(VI) exposure is associated with epigenetic dysregulation via an increase in the related histone-lysing methyltransferases expression which plays an essential role in Cr(VI)-induced cancer stem cell-like property and cell transformation ([@B65]). Another study confirmed that Cr(VI) can form protein-Cr-DNA adducts and silence tumor suppressor genes, as well as disrupt CTCF binding and nucleosome spacing ([@B66]). In addition, Clementino stated that Cr(VI)is related to oxidative stress and metabolic reprogramming, which contribute to tumorigenesis by participating in enhancement of the anti-apoptosis ability and rapid proliferation of cells ([@B67]). Therefore, additional high-qualify studies are needed to further explore the carcinogenesis of Cr(VI) exposure.

Limitations
-----------

There are some limitations in the present meta-analysis. Although we used the Begg\'s funnel plot and Egger\'s test and found no publication bias, slight publication bias is unavoidable. Owing to the occupational specificity and sex limitations, the study population comprised mostly male workers and specific sex-related SMRs were lacking. Therefore, the finding that high cancer deaths existed among male workers is acceptable. In addition, in a cohort study from 1971 to 1986 among 33,503 concrete workers, Knutsson et al. found that risk of cancer was high in female concrete workers (SIR = 1.17; 95% CI: 1.03--1.10) ([@B50]); further evidence is needed to verify this relationship. It should be noted that all studies included in this analysis comprised adults rather than children as the study population, as well as workers exposed to Cr(VI) rather than the general population; therefore, the results should not be generalized or applied to populations other than those who are exposed to Cr(VI). An additional limitation was that the included cohorts were from Europe, North America and Asia, with no available reports from other geographical areas available. For SMR studies, 70% were from Europe, 22% from North America, and 8% from Asia. For SIR studies, 82% were from Europe, 12% from North America, and 6% from Asia. Therefore, the estimates are largely dominated by the European cohorts. Nevertheless, these cohorts may provide more accurate and consistent baseline data compared with others owing to their large sample size and similar geographical conditions.

Conclusions {#s5}
===========

In summary, our meta-analysis provides evidence to support the association between exposure to Cr(VI) and increased mortality and incidence of some cancers. Based on our results, Cr(VI) exposure is related to a high-risk of death owing to lung, larynx, bladder, kidney, testicular, bone, and thyroid cancer. In addition, Cr(VI) exposed workers are at elevated risk of cancers of the respiratory system, buccal cavity, pharynx, prostate, and stomach. As with all meta-analyses, publication bias, and heterogeneity cannot be entirely eliminated. These findings require the support of well-designed cohort studies which are capable of addressing the problem of accurate measurement of exposure dose and time and potential confounders in the relationship between exposure to Cr(VI) and cancer.
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